Abstract
Aims/hypothesis Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure hospitalisations in individuals with type 2 diabetes.
Here, we performed a pre-specified analysis to examine whether sex modifies these effects. Methods The DECLARE-TIMI 58 trial randomised 17,160 patients with type 2 diabetes with or at risk for atherosclerotic disease to dapagliflozin or placebo (median follow-up 4.2 years).
The dual efficacy outcomes were CV death or heart failure hospitalisations, and major adverse cardiovascular events (MACE; CV death, myocardial infarction or ischaemic stroke). The renal-specific composite outcome was a sustained >= 40% drop in eGFR to <60 ml min(-1) [1.73 m](-2), new end-stage renal disease or renal death.
Cox models were run separately by sex with treatment-by-sex interaction testing for each outcome. Results At baseline, women (n = 6422, 37.4%) had higher HbA(1c), longer type 2 diabetes duration, and were on fewer glucose-lowering medications.
There was no evidence of modification of the effect of dapagliflozin by sex for (1) CV death or heart failure hospitalisations: women (3.8% vs 4.5%; HR 0.84, 95% CI 0.66, 1.07) and men (5.3% vs 6.4%; HR 0.83, 95% CI 0.71, 0.96; p(interaction) = 0.90); (2) MACE: women (6.3% vs 6.8%; HR 0.93, 95% CI 0.77, 1.12) and men (10.0% vs 10.7%; HR 0.93, 95% CI 0.83, 1.05; p(interaction) = 0.99); or (3) renal-specific composite: women (1.4% vs 2.8%; HR 0.50, 95% CI 0.35, 0.70) and men (1.5% vs 2.5%; HR 0.55, 95% CI 0.42, 0.73; p(interaction) = 0.64). The overall safety profile of dapagliflozin was similar for women and men.
Conclusions/interpretation Dapagliflozin offers comparable CV and renal benefits and a comparable safety profile in women and men.